コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 which HCV persists during chronic infection remain to be clarified.
2 eromatous lesions for these arterial regions remain to be clarified.
3 s, but many aspects of the sensing mechanism remain to be clarified.
4 The underlying mechanisms remain to be clarified.
5 However, the underlying mechanisms remain to be clarified.
6 ic causes for approximately 20% of the cases remain to be clarified.
7 C in HCC; however, the roles of MEF2C in HCC remain to be clarified.
8 presence of ascites in the pediatric setting remain to be clarified.
9 eptors in endothelial inflammatory responses remain to be clarified.
10 HMPV life cycle impacted by these functions remain to be clarified.
11 The pathogenesis and optimal treatments remain to be clarified.
12 aptation," "stress response," or "apoptosis" remain to be clarified.
13 pathways controlling joint formation largely remain to be clarified.
14 signals and their interactions in dendrites remain to be clarified.
15 regulation and possible synergy between them remain to be clarified.
16 ural mechanisms underlying this coordination remain to be clarified.
17 s by which FA exerts chemopreventive effects remain to be clarified.
18 l and clinical consequences of these changes remain to be clarified.
19 ders are thought to be high, but exact rates remain to be clarified.
20 ediated destruction of the tumor vasculature remain to be clarified.
21 volved and the therapeutic potential of MSCs remain to be clarified.
22 ymes that catalyze the addition of the tails remain to be clarified.
23 ms by which ASPP2 suppresses tumor formation remain to be clarified.
24 eta-cell death in T1D and their target genes remain to be clarified.
25 n-induced autophagy, apoptosis, and necrosis remain to be clarified.
26 operties, resulting in neuronal dysfunction, remain to be clarified.
27 Mechanisms of acute brain injury after ICH remain to be clarified.
28 ction as oxidases or nitric oxide reductases remain to be clarified.
29 t the factors that control import and export remain to be clarified.
30 's diseases, the causes of neurodegeneration remain to be clarified.
31 plants and their physiological significance remain to be clarified.
32 anisms of Ang II-induced myocardial fibrosis remain to be clarified.
33 e hippocampus after global cerebral ischemia remain to be clarified.
34 nocycline protection appear multifaceted and remain to be clarified.
35 talization via telomerase independent means, remain to be clarified.
36 their integration with other cell functions remain to be clarified.
37 lecular mechanisms of this process, however, remain to be clarified.
38 nderlying this specific tumor susceptibility remain to be clarified.
39 The mechanisms controlling FUTIV expression remain to be clarified.
40 hypothalamic inhibitory factor preparations remain to be clarified.
41 port across the additional plastid membranes remains to be clarified.
42 l, Cav2.2, in diabetic nephropathy, however, remains to be clarified.
43 ther these observations are causally related remains to be clarified.
44 n mitochondria, but its function there still remains to be clarified.
45 role of Ang2 in postnatal neovascularization remains to be clarified.
46 nd the definition of conduction disturbances remains to be clarified.
47 potential role of the variable NH2 terminus remains to be clarified.
48 utations on transcriptional regulation in WM remains to be clarified.
49 lved in disease in vivo, how it participates remains to be clarified.
50 ed DNA, but their role in DNA repair in vivo remains to be clarified.
51 for the demographic effects documented here remains to be clarified.
52 the anterior part of the temporal lobe (ATL) remains to be clarified.
53 basis for Waldenstrom macroglobulinemia (WM) remains to be clarified.
54 o be a puzzling disease and the pathogenesis remains to be clarified.
55 owever, their role during parasite infection remains to be clarified.
56 eir secondary structure in mineral formation remains to be clarified.
57 icroenvironment to promote GBM cell invasion remains to be clarified.
58 idual NKRs to viral clearance or persistence remains to be clarified.
59 the 19H variant on intestinal ABCG8 feature remains to be clarified.
60 inated regime and the satellites' production remains to be clarified.
61 D; >/= 50% dysplastic cells in 2-3 lineages) remains to be clarified.
62 recruitment of a pre-existing motor network remains to be clarified.
63 GA-mediated gynoecium and fruit development remains to be clarified.
64 h-risk diffuse large B-cell lymphoma (DLBCL) remains to be clarified.
65 by which the cell fate is controlled by p53 remains to be clarified.
66 in skeletal muscle, neuropathic muscle pain remains to be clarified.
67 nism of action of complement in this process remains to be clarified.
68 The role of HIV itself remains to be clarified.
69 s and cytoplasm is required for coactivation remains to be clarified.
70 in, although the nature of the neurotoxicity remains to be clarified.
71 nt human cannabinoid CB(1) receptor variants remains to be clarified.
72 ntribution of PTB to the malignant phenotype remains to be clarified.
73 ance in rats and that its essential function remains to be clarified.
74 r, the identity of the ion channels involved remains to be clarified.
75 p on ibrutinib, although the molecular basis remains to be clarified.
76 factors involved in cellular differentiation remains to be clarified.
77 LDL and the oxidative stress of macrophages remains to be clarified.
78 tic basis of this microenvironment, however, remains to be clarified.
79 , the mechanism by which they function still remains to be clarified.
80 heparin binds to other fibrin(ogen) regions remains to be clarified.
81 ese measures and gut motility or sensitivity remains to be clarified.
82 relative contribution of acetate metabolism remains to be clarified.
83 signaling pathways and transcription factors remains to be clarified.
84 carcinoma risk factors and bile duct cancer remains to be clarified.
85 a NMDA antagonist by a mechanism that still remains to be clarified.
86 e-bound receptor or at an intracellular site remains to be clarified.
87 s for this enzyme-vesicle "hopping" behavior remains to be clarified.
88 zation in the amino acid economy of the host remains to be clarified.
89 nal portion, including putative TMD1 and -2, remains to be clarified.
91 a viable treatment option, but some aspects remain to be clarified as to the efficacy of bone substi
92 nderlying reduced insulin degradation in AAs remains to be clarified, as does the relative importance
95 ional consequences of this phenomenon, which remain to be clarified, could be specific for different
96 lization in the retention of duplicate genes remain to be clarified, especially for higher eukaryotes
98 cells under miscellaneous conditions, but it remains to be clarified how RASSF6 exerts tumor-suppress
101 3) fatty acids plays a role in tumorigenesis remains to be clarified in well qualified experimental m
103 Although the exact source and cell type remains to be clarified, our greater understanding of th
104 pendent mechanism, whose molecular substrate remains to be clarified, targets SVs to synaptic boutons
106 ns of joint and bone damage were present, it remained to be clarified whether it was a consequence of
108 s, e.g., decreased GluR1 phosphorylation, it remains to be clarified whether MK-886 can affect GluR1
109 ed by recent studies in human and monkey, it remains to be clarified with an in-depth, systematic app
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。